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Purpose: In Europe, pancreatic cancer (PC) accounts
for approximately 2.6% of all new cancer cases and is
the fourth leading cause of cancer-related death. Despite
substantial morbidity and mortality, limited data are
available describing real-world treatment patterns and
health care resource use in any European country. We
evaluated PC-related treatment patterns and associated
health care resource use among patients with metastatic
PC in the United Kingdom and France.
Methods: One hundred three oncology specialists (53
in France and 50 in the United Kingdom) abstracted data
from medical records of 400 patients whom they treated
for metastatic PC. Eligible patients had a diagnosis of
metastatic PC at age 18 years or older between January 1,
2009, and December 31, 2012; had Z3 months of
follow-up time beginning at metastatic diagnosis; and
received at least 1 cancer-directed therapy for metastatic
disease. Information on patient demographics, Eastern
Cooperative Oncology Group performance status, loca-
tion of primary tumor, presence of comorbidities, adverse
events, and complications were collected. Data on cancer-
directed treatments and supportive care measures were
evaluated. All analyses were descriptive.
Findings: Approximately two thirds of patients were
men, and median age at metastatic disease diagnosis
was 62.2 years. Nearly all patients (97.3%) received
chemotherapy to treat metastatic disease, 9.3% received*These authors contributed equally to this work.
†Current afﬁliation: Evidera.
June 2015radiation therapy, and 7.8% received a targeted therapy.
Overall, the most frequently administered ﬁrst-line regi-
mens for metastatic disease were gemcitabine alone
(46.0%), a combination chemotherapy regimen consist-
ing of oxaliplatin, irinotecan, ﬂuorouracil, and leuco-
vorin (FOLFIRINOX; 20.1%); gemcitabine/capecitabine
(10.8%); and gemcitabine/oxaliplatin (9.5%). Approx-
imately 40% of patients in France and 15% of patients
in the United Kingdom received second-line systemic
therapy, whereas 20% of patients in France and 3.4% of
patients in the United Kingdom received third-line
systemic therapy for metastatic disease. Overall, 52.5%
of patients experienced at least one complication of PC.
More than two thirds of patients had Z1 ofﬁce visit
unrelated to chemotherapy administration, 54.0% had
Z1 inpatient hospitalization, 36.8% hadZ1 emergency
department visit, and 25.3% had Z1 pain management
clinic visit. A total of 26.5% of patients in France and
42.5% in the United Kingdom entered hospice or long-
term care.
Implications: This study provides new, detailed
information for patients with metastatic PC in real-
world settings in 2 European countries. A small
proportion of patients received 41 line of systemic
therapy for metastatic disease, which is likely due toAccepted for publication March 12, 2015.
http://dx.doi.org/10.1016/j.clinthera.2015.03.016
0149-2918/$ - see front matter
& 2015 The Authors. Published by Elsevier HS Journals, Inc. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Clinical Therapeuticsthe aggressiveness of this disease and the lack of
effective therapeutic options. (Clin Ther.
2015;37:1301–1316) & 2015 The Authors. Published
by Elsevier HS Journals, Inc.
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INTRODUCTION
Pancreatic cancer accounts for approximately 2.6% of
all new cancer cases in both sexes in Europe.1 In the
United Kingdom, the total incidence of pancreatic
cancer remained stable overall between 1975 and
1977 and 2008 and 2010, given a decrease in
incidence in men and a similar increase in women
during these periods.2 In contrast, an increase in the
incidence in both sexes was reported in Burgundy,
France, between 1981 and 2005 for men (from 5.7 in
1981–1985 to 7.9 per 100,000 in 2001–2005) and
women (from 2.6 in 1981–1985 to 4.6 per 100,000 in
2001–2005).3 To our knowledge, the apparent
disparity in changes in sex-speciﬁc incidence rates in
the United Kingdom and France over time has not
been documented in the literature. Although there is
no guarantee that cancer incidence rates will change in
parallel in all strata (eg, by age, sex, and region or
country), underlying regional differences in risk fac-
tors demonstrated to affect incidence rates (eg, smok-
ing and obesity) may play a part in these seemingly
contradictory ﬁndings.2
In Europe, where pancreatic cancer is the fourth
leading cause of cancer-related death and has an increas-
ing mortality rate in both sexes, it is predicted that 82,300
deaths will occur in 2014 due to this disease.4 Part of the
reason for a high case-fatality rate in pancreatic cancer is
that many patients do not experience symptoms until the
disease is in an advanced stage, leading to delays in
diagnosis and subsequent treatment initiation. In addi-
tion, despite substantial research efforts, until relatively
recently, there has been little therapeutic advancement in
the treatment of this disease in the adjuvant setting5,6 or
in advanced disease.1,7,8
Leucovorin, 5-ﬂuorouracil (5-FU), irinotecan,
and oxaliplatin (FOLFIRINOX) and the gemcitabine
plus nab-paclitaxel combination represent the most
recent advancements for the ﬁrst-line treatment of
metastatic disease. Conroy et al,8 of the Groupe
Tumeurs Digestives of Unicancer and the PRODIGE1302Intergroup, demonstrated that patients with an
Eastern Cooperative Oncology Group (ECOG)
performance status (PS) score of 0 or 1 receiving
FOLFIRINOX achieved a median overall survival of
11.1 months compared with 6.8 months in patients
who received gemcitabine (hazard ratio ¼ 0.57; 95%
CI, 0.45–0.73; P o 0.001). Patients who received
FOLFIRINOX also experienced signiﬁcantly increased
toxicity relative to gemcitabine alone. Comparable
results have been achieved in routine clinical practice
in France, where the safety and efﬁcacy of this regimen
were evaluated.9 In addition, real-world data from a
large, integrated oncology network in the United
States demonstrated an increase in the use of FOL-
FIRINOX10 after the availability of data from the
randomized study described by Conroy et al.8 The
overall survival data from a real-world setting pre-
sented by Cartwright et al10 were signiﬁcantly better
for FOLFIRINOX than for gemcitabine alone (P o
0.001), although the magnitude of effect was not as
large as that reported in the results of the clinical trial
described by Conroy et al.8 To achieve a more
favorable beneﬁt–risk proﬁle for patients, efforts are
ongoing to evaluate the safety and efﬁcacy of modiﬁed
FOLFIRINOX regimens. Nab-paclitaxel, in com-
bination with gemcitabine, has been approved by the
US Food and Drug Administration11 and the
European Medicines Agency (EMA)12 for patients
with a Karnofsky PS of 70 or higher based on
results reported by Von Hoff et al.7 Clinical trial
results found that the median overall survival for the
nab-paclitaxel combination was signiﬁcantly better
than for gemcitabine alone (median ¼ 8.5 months
[vs] 6.7 months; hazard ratio ¼ 0.72; 95% CI, 0.62–
0.83; P o 0.001), and toxicity was greater among
patients treated with the combination.7
Although pancreatic cancer is a major cause of
morbidity and mortality in economically developed
nations, only limited data have been published de-
scribing real-world treatment patterns and health care
resource use associated with the treatment of pancre-
atic cancer in any European country. As part of our
objectives, we set out to characterize whether FOL-
FIRINOX use is increasing in select countries in
Europe. Furthermore, to our knowledge, there are
limited data on the frequency of complications in this
population and the extent to which these aspects of
the disease are associated with health care resource
use. Therefore, we undertook a study to evaluateVolume 37 Number 6
E.N. Smyth et al.outcomes, including health care resource use, among
patients with metastatic pancreatic cancer treated in
France and the United Kingdom.
MATERIALS AND METHODS
This was a retrospective medical research study that
evaluated treatments and outcomes as documented in
medical records for patients with metastatic pancreatic
cancer who were diagnosed between January 1, 2009,
and December 31, 2012, and who received cancer-
directed therapies in France and the United Kingdom.
Data Source and Study Design
A purposive sampling design was used to ensure
that information was obtained on a similar number of
patients in each country; consequently, among the
total 103 physicians recruited to participate, 53 were
located in France and 50 were located in the United
Kingdom. Physicians were required to be caring for a
minimum of 6 patients with metastatic pancreatic
adenocarcinoma on or after January 1, 2009, and to
have been in clinical practice for 5 to 35 years. Each
physician was instructed to select records of his or her
own patients for abstraction using a quasi-random
selection approach based on the ﬁrst initial of each
potential patient’s surname. A customized data col-
lection form was developed based on the study’s
speciﬁc objectives and was administered via a secure,
online interface. Data were collected without identi-
ﬁcation of the patient or physician to the study
sponsor and authors (data collection was facilitated
by a global research ﬁrm, A Plus A Medical Market
Research, Lyon, France). As a retrospective medical
research study, country-speciﬁc ethical review board
requirements were reviewed, and it was determined
that this study was exempt in both France and the
United Kingdom. Furthermore, the study was judged
to be exempt from informed consent requirements by
the RTI International Institutional Review Board.
Patient Sample Description
Eligible patients were aged at least 18 years and
were diagnosed with metastatic pancreatic adeno-
carcinoma between January 1, 2009, and December
31, 2012. Patients could have been initially diag-
nosed with an earlier stage of pancreatic cancer
and progressed to metastatic disease if the diag-
nosis of metastatic disease was made during the
study period. Patients must have received at least 1June 2015cancer-directed therapy for metastatic disease
(ie, systemic chemotherapy, a targeted systemic
therapy, radiation therapy, or surgery) during the
study period. To ensure a distribution of diagnosis
dates and to observe relevant changes in treatment
patterns, soft quotas were imposed in the ratio of
1:2:2:2 for the year of diagnosis of metastatic
disease for 2009, 2010, 2011, and 2012, respec-
tively, such that for every 1 patient for whom data
were collected in 2009, data for 2 patients were
collected each year: 2010, 2011, and 2012. In
addition, we required a minimum follow-up time
in the medical record of at least 3 months after
the diagnosis of metastatic pancreatic adenocarci-
noma. Patients with pancreatic neuroendocrine tu-
mor (carcinoid and other types), those diagnosed
with another primary malignancy (other than non-
melanoma skin cancer) at any time during the
follow-up period, as well as those enrolled in an
interventional clinical trial related to pancreatic
cancer for any period during their treatment were
excluded from this study. Patients who participated
in observational studies were eligible to participate.
Study Measures
Patient characteristics abstracted from the medical
records were age, sex, ethnic origin (for the United
Kingdom only; ethnicity was not collected in France
due to local laws on data privacy), type of insurance,
ECOG PS13 at ﬁrst diagnosis, location of primary
pancreatic tumor (head, body, tail, and other), and
presence of comorbidities. Treatments evaluated
included systemic chemotherapy and/or targeted
therapy, radiation therapy, and surgery with either
curative intent or palliation, accounting for combi-
nations and line of therapy. Supportive care measures
and treatments for well-known complications of
metastatic pancreatic cancer were also evaluated. Na-
tional Comprehensive Cancer Network guidelines and
the clinical experience of the study team were used to
inform which treatments were evaluated as part of the
study.14,15
A complication was deﬁned as a disease, condition,
or injury that developed during the treatment of
pancreatic cancer and that could be reasonably attrib-
uted to the pancreatic cancer rather than its treatment.
Measures of supportive care were evaluated and
deﬁned as the management of pain and other distress-
ing symptoms to reduce suffering and support quality1303
Clinical Therapeuticsof life. The frequencies of Grade 3 or 4 adverse events,
as documented in product labeling in addition to
reasons for discontinuation of chemotherapy and/or
targeted therapy, were also explored.
Health care use measures that were assessed in-
cluded hospitalizations, additional outpatient ofﬁce
visits unrelated to systemic treatment administration,
emergency department admissions, and visits to pain
management clinics. End-of-life care was evaluated
based on reported enrollment in long-term-care facili-
ties and hospice care.
Participating physician characteristics were collected,
including the number of years in practice, specialty,
average number of metastatic pancreatic cancer patients
treated in a year, and geographic region of practice.
Statistical Analyses
Descriptive analyses were performed to display
means, SDs, medians, and ranges for continuous
variables and frequency distributions for categorical
variables. All analyses were conducted for the entire
study population and separately by country. Further-
more, we assessed FOLFIRINOX and gemcitabine
use as ﬁrst-line therapy for metastatic disease, strati-
ﬁed by ECOG PS score in each country, and the top
3 most frequent ﬁrst-line regimens used by year of
diagnosis. All analyses were conducted using
SAS version 9.3 software (SAS Institute Inc, Cary,
North Carolina).Table I. Physician characteristics.
Characteristic France (n ¼ 53)
Patients with pancreatic adenocarcinoma (any stage) treated on or after Jan
Mean (SD) 113 (111.80)
Years in practice
Mean (SD) 13 (5.16)
Median 12
Range (minimum, maximum) (5, 30)
France o —————————————
Telephone code 01 (Paris area) 14 (26.42)
Telephone code 02 (northwest) 5 (9.43)
Telephone code 03 (north and northeast) 11 (20.75)
Telephone code 04 (southeast) 13 (24.53)
Telephone code 05 (southwest) 10 (18.87)
United Kingdom
North –
Midlands and east –
Greater London and southeast –
Southwest –
Scotland, Wales, and Northern Ireland –
1304RESULTS
Physician Characteristics
Table I presents characteristics of participating
physicians. The physicians had an average of 12
years of practice experience and all were oncology
specialists. Participating physicians reported that
between January 1, 2009, and December 31, 2012,
they treated an average of 113 (France) and 135
(United Kingdom) patients with pancreatic adenocar-
cinoma (of any stage). The geographic distribution of
physicians across the various regions in France and
the United Kingdom were based on soft quotas, which
were imposed to ensure that data would be
contributed by physicians practicing in as many
regions of each country as possible. To achieve this
representation, fewer physicians participated from
larger metropolitan cities such as Paris, France,
relative to the size of the population.
Patient Characteristics and Disease History
Four hundred patients were included in the study
(200 patients in each country). Of these, 327 patients
presented initially with metastatic disease and the
remaining 73 had been diagnosed at earlier stages
and progressed to metastatic disease. Stage at initial
diagnosis was unknown for 1 patient in the United
Kingdom and was assumed to be metastatic disease in
the analysis. Table II presents patients’ demographic
and other characteristics. The majority of patientsUnited Kingdom (n ¼ 50) Total (N ¼ 153)
uary 1, 2009
135 (117.29) 124 (114.46)
11 (4.46) 12 (4.86)
11 11
(5, 27) (5, 30)
——————— n (%) ———————————————————— 4
– –
– –
– –
– –
– –
6 (12.00) –
10 (20.00) –
17 (34.00) –
9 (18.00) –
8 (16.00) –
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Table II. Patient characteristics.
Characteristic France (n ¼ 200) United Kingdom (n ¼ 200) Total (N ¼ 400)
Age at metastatic disease diagnosis, y
Mean (SD) 63.8 (8.42) 59.9 (9.37) 61.8 (9.1)
Median 63.6 60.3 62.2
Range (minimum, maximum) (40.5, 86.8) (28.6, 80.7) (28.6, 86.8)
Age distribution, y o ———————————————————— n (%) ———————————————————— 4
18–44 14 (7.00) 3 (1.50) 17 (4.25)
45–54 47 (23.50) 25 (12.50) 72 (18.00)
55–64 72 (36.00) 87 (43.50) 159 (39.75)
65–74 59 (29.50) 68 (34.00) 127 (31.75)
75þ 8 (4.00) 17 (8.50) 25 (6.25)
Sex
Male 131 (65.50) 122 (61.00) 253 (63.25)
Female 69 (34.50) 78 (39.00) 147 (36.75)
Ethnic origin*
White/Caucasian – 174 (87.00) –
African/black – 16 (8.00) –
Asian or Paciﬁc Islander – 9 (4.50) –
Other – 1 (0.50) –
Don’t know – – –
Supplemental private insurance
Yes 91 (45.50) 18 (9.00) 109 (27.25)
No 33 (16.50) 164 (82.00) 197 (49.25)
Don’t know 76 (38.00) 18 (9.00) 94 (23.50)
ECOG PS
Mean (SD) 1.2 (0.8) 1.2 (0.7) 1.2 (0.7)
Distribution of ECOG PS†
0 31 (15.50) 26 (13.00) 57 (14.25)
1 105 (52.50) 116 (58.00) 221 (55.25)
2 57 (28.50) 49 (24.50) 106 (26.50)
3 6 (3.00) 7 (3.50) 13 (3.25)
4 1 (0.50) 1 (0.50) 2 (0.50)
Don’t know – 1 (0.50) 1 (0.25)
Location of the primary pancreatic tumor
Head 95 (47.50) 114 (57.00) 209 (52.25)
Body 63 (31.50) 64 (32.00) 127 (31.75)
Tail 33 (16.50) 17 (8.50) 50 (12.50)
Other 3 (1.50) – 3 (0.75)
Don’t know 6 (3.00) 5 (2.50) 11 (2.75)
ECOG ¼ Eastern Cooperative Oncology Group; PS ¼ performance status.
*Ethnic origin not asked in France.
†Source: Reference 13.
E.N. Smyth et al.were men (63.3%), and the median age at the time of
metastatic disease diagnosis was 62.2 years, with
more than 70% of patients between ages 55 and 74
years. More than two thirds of patients had an ECOG
PS score of 0 or 1 when metastatic disease was
diagnosed, with a mean ECOG PS score of 1.2 for
patients in both countries.
Figure 1 presents comorbidities recorded in at least
5% of patients at the time of metastatic disease
diagnosis. Hypertension and diabetes mellitus were
the most commonly reported comorbidities. MoreJune 2015than 40% of patients had a smoking history (ie,
were either current or former smokers).
Treatment Patterns
First-Line Therapy for Metastatic Disease
Nearly all patients (97.3%) received chemotherapy to
treat metastatic disease: 9.3% received radiation therapy
and 7.8% received a targeted therapy (categories not
mutually exclusive). Among the 389 patients who re-
ceived chemotherapy, only 37 had received prior treat-
ment for earlier-stage disease (adjuvant chemotherapy or1305
History of myocardial
infarction
Obesity
Chronic pulmonary
disease
Depression
Current smoker
Former smoker
Diabetes
Hypertension
0 10 20 30 40 50
UK
France
Figure 1. Comorbidities recorded in at least 5%
of patients at the time of metastatic
disease diagnosis. UK ¼ United
Kingdom.
Clinical Therapeuticschemotherapy for locally advanced disease). As illustrated
in Table III, overall, the most commonly administered
regimens used as ﬁrst-line therapy for metastatic disease
were gemcitabine alone (46.0%), FOLFIRINOX
(20.1%), gemcitabine plus capecitabine (10.8%), and
gemcitabine plus oxaliplatin (9.5%). In France, the most
commonly administered regimens were gemcitabine alone
(46.5%), FOLFIRINOX (28.3%), and gemcitabine plusTable III. First chemotherapy and targeted therapy for m
Type of Chemotherapy/Biological
Therapy Administered
France
(n ¼ 19
n
Gemcitabine 92 4
Gemcitabine þ erlotinib 3
Gemcitabine þ oxaliplatin 29 1
Gemcitabine þ cisplatin 3
Gemcitabine þ capecitabine 2
FOLFIRINOX (includes leucovorin þ
ﬂuorouracil þ irinotecan þ oxaliplatin)
56 2
Single-agent ﬂuoropyrimidine* 1
Fluoropyrimidine þ oxaliplatin† 11
Other/NA‡ 1
NA ¼ not available.
*Includes either ﬂuorouracil (bolus or continuous infusion) þ le
†Includes either ﬂuorouracil (bolus or continuous infusion) þ o
‡Includes cisplatin, “other regimen,” and “not available.”
1306oxaliplatin (14.7%). In the United Kingdom, the most
commonly administered regimens were gemcitabine alone
(45.6%), gemcitabine plus capecitabine (20.9%), and
FOLFIRINOX (11.5%). Given ongoing efforts to eval-
uate the efﬁcacy and safety of modiﬁed FOLFIRINOX
regimens, we sought to gather information regarding use
of such regimens in our study.16–18 In both countries, we
found that a small proportion (o2%) of patients received
a modiﬁed FOLFIRINOX regimen, which was charac-
terized as receiving less than the starting dose for 1 of the
drugs in the regimen, as recommended by Conroy et al8
(results not shown). This ﬁnding is not surprising, given
more recent publications for the modiﬁed doses relative
to the end of our data-collection period (ie, December
31, 2012).
We further analyzed the use of gemcitabine alone
and FOLFIRINOX, either of which was administered
to nearly two thirds of patients in the study. Figure 2
depicts the proportions of patients receiving these
regimens as the ﬁrst-line therapy for metastatic dis-
ease, stratiﬁed by ECOG PS score. In both countries, a
disproportionate number of patients with an ECOG
PS score of 0 were treated with FOLFIRINOX, and a
greater proportion of patients with an ECOG PS score
of 2 received gemcitabine alone.etastatic pancreatic adenocarcinoma.
8)
United Kingdom
(n ¼ 191)
Total
(N ¼ 389)
% n % n %
6.46 87 45.55 179 46.02
1.52 4 2.09 7 1.80
4.65 8 4.19 37 9.51
1.52 13 6.81 16 4.11
1.01 40 20.94 42 10.80
8.28 22 11.52 78 20.05
0.51 7 3.67 8 2.05
5.56 4 2.09 15 3.85
0.51 6 3.13 7 1.80
ucovorin or capecitabine alone.
xaliplatin or capecitabine þ oxaliplatin.
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Figure 2. Proportions of patients receiving these
regimens as the first-line therapy for
metastatic disease, stratified by
Eastern Cooperative Oncology Group
performance status (ECOG PS) score.
UK ¼ United Kingdom.
E.N. Smyth et al.Figure 3 presents a time-trend analysis of the 3
most frequently administered ﬁrst-line chemotherapy
regimens for metastatic disease. In both countries, a
progressive increase in the use of FOLFIRINOX over
the 4 study years is apparent.
Reasons for treatment discontinuation among patients
receiving each of the 3 most commonly administered ﬁrst-
line therapies for metastatic disease were assessed. The
most common reason for discontinuation of any of the
therapies was disease progression. For example, for
gemcitabine alone, 63.0% of patients in France and
43.7% in the United Kingdom discontinued for this
reason. The proportion of patients who discontinued due
to intolerance or toxicity varied somewhat by treatment
regimen and by country. Among patients receiving gemci-
tabine, 8.7% discontinued due to intolerance or toxicity inJune 2015France and 10.3% did so in the United Kingdom. For
those receiving gemcitabine and oxaliplatin or gemcitabine
and capecitabine, 10.3% and 2.8% of patients in France
and the United Kingdom, respectively, discontinued for
this reason. Among those receiving FOLFIRINOX, 17.9%
discontinued for intolerance or toxicity in France and
27.3% did so in the United Kingdom. Overall, treatment
was ongoing at the time of data reporting for approx-
imately 19% of patients receiving FOLFIRINOX as ﬁrst-
line therapy for metastatic disease. This proportion was
greater for patients receiving FOLFIRINOX compared
with patients receiving other treatments due to the
increased use of FOLFIRINOX during the later years that
patients were eligible for the study.
Second- and Third-Line Therapies for Metastatic
Disease
In France, 40.4% of patients (n ¼ 80) received
second-line systemic therapy for metastatic disease,
and 15.2% of patients (n ¼ 29) did so in the United
Kingdom. In France, the most commonly reported
therapies included gemcitabine (28.8%); combination
therapy with continuous-infusion 5-FU, oxaliplatin,
and leucovorin (17.5%); and capecitabine (10.0%). In
the United Kingdom, the most commonly reported
therapies included capecitabine (27.6%); combination
therapy with continuous-infusion 5-FU, oxaliplatin,
and leucovorin (24.1%); and gemcitabine (10.3%).
Sixteen patients in France (20.0%) and 1 patient in
the United Kingdom (3.4%) received third-line sys-
temic therapy for metastatic disease. In France, the
most commonly reported therapies included combina-
tion therapy with continuous-infusion 5-FU, irinote-
can, and leucovorin (31.3%); capecitabine (25.0%);
and gemcitabine (25.0%). The reporting physician did
not know the speciﬁc regimen received by the 1
patient in the United Kingdom.
Adverse Events and Complications
The evaluation of adverse events was restricted to those
documented as Grade 3 or 4 in the patient’s medical
record. Table IV presents the number and percentage of
patients who experienced Grade 3 or 4 adverse events
among those who received each of the 3 most commonly
administered ﬁrst-line therapies for metastatic disease.
In each country, there was variation in the proportion
of patients experiencing Grade 3 or 4 adverse events
across the top-3 most commonly administered ﬁrst-line
therapies for metastatic disease. Overall, the most1307
France
2009 2010 2011 2012
2009 2010 2011 2012
Year
Year
P
er
ce
nt
 o
f 
P
at
ie
nt
s
P
er
ce
nt
 o
f 
P
at
ie
nt
s
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
100.0
90.0
80.0
70.0
60.0
50.0
40.0
30.0
20.0
10.0
0.0
UK
Gemcitabine Gemcitabine +
oxaliplatin
FOLFIRINOX
Gemcitabine Capecitabine +
gemacitabine
FOLFIRINOX
Figure 3. A time-trend analysis of the 3 most
frequently administered first-line che-
motherapy regimens for metastatic dis-
ease. In both countries, a progressive
increase in the use of a combination
chemotherapy regimen consisting of ox-
aliplatin, irinotecan, fluorouracil, and
leucovorin (FOLFIRINOX) over the 4
study years is apparent. Note: In 2009
only, gemcitabine þ cisplatin was
among the three most frequently admi-
nistered first chemotherapy regimens for
metastatic disease in the UK, but it is
not shown in this figure. Although
FOLFIRINOX was not among the three
most frequently administered first che-
motherapy regimens for metastatic dis-
ease in the UK in 2009, it was included
in the group beginning in 2010 and is
shown in this figure for all years.
Clinical Therapeuticscommon adverse events recorded were neutropenic fever,
thrombocytopenia, and gastrointestinal events.
Overall, 52.5% of patients experienced at least one
complication of metastatic pancreatic cancer (not pre-
sented in tabular form). The most commonly experi-
enced complications were cachexia (24.8%), biliary
obstruction (18.8%), malnutrition (17.0%), depression
(13.5 %), and intractable ascites (12.0%). In France,130846.5% of patients experienced complications, with the
most common being cachexia (21.5%), depression
(17.5%), malnutrition (17.0%), biliary obstruction
(16.0%), and intractable ascites (12.0%). In the United
Kingdom, 58.5% of patients experienced a complica-
tion, with the most common being cachexia (28.0%),
biliary obstruction (21.5%), malnutrition (17.0%),
intractable ascites (12.0%), and depression (9.5%).
Supportive Care
The majority of patients (92.0%) received at least one
speciﬁc type of therapy for supportive care (Table V).
Sixty-seven percent received pharmacologic or procedural
therapy for pain control, 50.0% received antiemetics,
25.8% were administered antibiotics, and 26.0% re-
quired blood transfusions. Hematopoietic growth factors
were administered to 26.5% of patients in France but to
only 3.0% in the United Kingdom. Twenty-six percent of
patients in France and 9.5% in the United Kingdom
received therapy for distress management, deﬁned as the
identiﬁcation and treatment of psychosocial problems in
patients with cancer.19
HEALTH CARE RESOURCE USE
Table VI presents a summary of health care resource
use. As expected, most patients had at least 1 ofﬁce visit
(deﬁned as visit unrelated to the administration of
chemotherapy): 66.5% in France and 86.5% in the
United Kingdom. Among patients with at least 1 ofﬁce
visit, the median number of ofﬁce visits was 6 in both
countries. More than half (54.0%) had at least 1
inpatient hospitalization, and among this group,
41.7% had 1, 33.3% had 2, and 25.0% had 3 or
more inpatient hospitalizations. Among those with at
least 1 inpatient hospitalization, the median length of
stay overall was 8 days (10 days in France and 6 days in
the United Kingdom). Forty-ﬁve percent of patients in
France and 28.5% of patient in the United Kingdom
had at least 1 emergency department visit, and approx-
imately one quarter of the patients in both countries had
a pain management clinic visit. During the study
observation period, 26.5% (n ¼ 53) of patients in
France and 42.5% (n ¼ 85) in the United Kingdom
received end-of-life care, as deﬁned by enrollment in
either hospice care or a long-term-care facility.
DISCUSSION
Our study was a retrospective evaluation of medical
records of patients with metastatic pancreaticVolume 37 Number 6
Table IV. Grade 3 to 4 adverse events reported for the 3 most commonly administered first therapy regimens following metastatic disease
diagnosis.
Grade 3 or 4 Adverse Event*
France United Kingdom
Gemcitabine
(n ¼ 92)
FOLFIRINOX
(n ¼ 56)
Gemcitabine þ Oxaliplatin
(n ¼ 29)
Gemcitabine
(n ¼ 87)
Gemcitabine þ Capecitabine
(n ¼ 40)
FOLFIRINOX
(n ¼ 22)
n % n % n % n % n % n %
Any 6 6.52 11 19.64 2 6.90 6 6.90 6 15.00 8 36.36
Neutropenia 2 2.17 2 3.57 – – – – 1 2.50 3 13.64
Neutropenic fever – – 5 8.93 – – 2 2.30 1 2.50 4 18.18
Thrombocytopenia 3 3.26 5 8.93 – – 3 3.45 – – 1 4.55
Bleeding – – 1 1.79 – – – – – – – –
Anemia 3 3.26 3 5.36 1 3.45 – – 1 2.50 – –
Eye toxicity – – – – – – – – – – 1 4.55
Palmar-plantar (hand-foot) syndrome – – 3 5.36 – – – – 4 10.00 – –
Asthenia 3 3.26 4 7.14 1 3.45 – – 1 2.50 – –
Fatigue, lethargy, general deterioration 2 2.17 2 3.57 1 3.45 3 3.45 1 2.50 – –
Pain (abdominal, general, arthralgia, or myalgia) – – 1 1.79 – – – – – – – –
Paresthesia/sensory neuropathy – – 5 8.93 2 6.90 – – – – 1 4.55
Edema 1 1.09 – – – – – – – – – –
Infection 1 1.09 – – – – – – – – – –
Gastrointestinal events (diarrhea, nausea/vomiting, stomatitis) 1 1.09 4 7.14 – – – – 2 5.00 3 13.64
Abnormal liver blood tests (alkaline phosphatase
elevated, ALT (SGPT) elevated, AST (SGOT)
elevated, bilirubin elevated)
– – 1 1.79 – – – – – – – –
Other – – – – – – – – 1 2.50 – –
ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; FOLFIRINOX ¼ a combination chemotherapy regimen consisting of oxaliplatin, irinotecan,
ﬂuorouracil, and leucovorin; SGOT ¼ serum glutamic oxaloacetic transaminase; SGPT ¼ serum glutamic pyruvate transaminase.
*Not mutually exclusive.
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Table V. Supportive care.
Supportive Care*
France
(n ¼ 200)
United Kingdom
(n ¼ 200)
Total
(N ¼ 400)
n % n % n %
Pain control 134 67.00 134 67.00 268 67.00
Opiate analgesic 129 64.50 127 63.50 256 64.00
Other analgesic 40 20.00 63 31.50 103 25.75
Radiotherapy 9 4.50 11 5.50 20 5.00
Percutaneous celiac plexus blockade 2 1.00 5 2.50 7 1.75
Splanchnic nerve block 2 1.00 2 1.00 4 1.00
Psychological intervention 65 32.50 4 2.00 69 17.25
Sedation for refractory pain 9 4.50 1 0.50 10 2.50
Epidural infusions – – 1 0.50 1 0.25
Other – – 1 0.50 1 0.25
Distress management 52 26.00 19 9.50 71 17.75
Antiemetic 113 56.50 87 43.50 200 50.00
Antibiotic 54 27.00 49 24.50 103 25.75
Antibacterial 9 4.50 14 7.00 23 5.75
Antifungal 18 9.00 6 3.00 24 6.00
Antiviral 1 0.50 – – 1 0.25
Transfusion 59 29.50 45 22.50 104 26.00
Palliative surgery 2 1.00 – – 2 0.50
Bypass of intestinal obstruction 2 1.00 – – 2 0.50
Embolization 2 1.00 2 1.00 4 1.00
Endoscopic stent placement 38 19.00 29 14.50 67 16.75
Percutaneous biliary drainage with stent placement 11 5.50 6 3.00 17 4.25
Percutaneous biliary drainage without stent placement – – 1 0.50 1 0.25
Growth factors 53 26.50 6 3.00 59 14.75
GCSF (eg, ﬁlgrastim, pegﬁlgrastim) 43 21.50 6 3.00 49 12.25
GM-CSF (eg, molgramostim, sargramostim) 2 1.00 – – 2 0.50
Erythropoiesis stimulating agent (eg, erythropoietin,
epoetin alpha, epoetin beta, darbepoetin alpha, methoxy
polyethylene glycol-epoetin beta)
37 18.50 – – 37 9.25
Other 2 1.00 3 1.50 5 1.25
No supportive care 10 5.00 12 6.00 22 5.50
Don’t know – – 9 4.50 9 2.25
GCSF ¼ granulocyte colony-stimulating factor; GM-CSF ¼ granulocyte-macrophage colony-stimulating factor.
*Supportive care focuses on management of pain and other distressing symptoms to reduce suffering and support quality
of life.
Clinical Therapeuticsadenocarcinoma who received cancer-directed therapy
in France and the United Kingdom. The primary
objective was to describe patterns of care in both
countries rather than to compare the treatment1310patterns and outcomes between the 2 countries.
Consistent with this objective, and with limited ability
to adjust for potentially confounding factors due to
the nature of the study, no formal statistical testsVolume 37 Number 6
Table VI. Health care resource use.
Health Care Use
France
(n ¼ 200)
United Kingdom
(n ¼ 200)
Total Cohort
(N ¼ 400)
Ofﬁce visit
n (%) 133 (66.50) 173 (86.50) 306 (76.50)
Mean (SD) 8.1 (7.3) 8.8 (7.1) 8.5 (7.1)
Median 6 6 6
Range (minimum, maximum) (1, 35) (1, 35) (1, 35)
Emergency department visit
n (%) 90 (45.00) 57 (28.50) 147 (36.75)
Mean (SD) 2.1 (1.5) 2.1 (2.0) 2.1 (1.7)
Median 2 1 2
Range (minimum, maximum) (1, 9) (1, 9) (1, 9)
Pain management clinic visit
n (%) 51 (25.50) 50 (25.00) 101 (25.25)
Mean (SD) 2.2 (1.6) 3.2 (2.1) 2.7 (1.9)
Median 2 3 2
Range (minimum, maximum) (1, 8) (1, 12) (1, 12)
Inpatient stay*
n (%) 115 (57.50) 101 (50.50) 216 (54.00)
Mean (SD) 2.2 (1.8) 2.0 (1.5) 2.1 (1.7)
Median 2 2 2
Range (minimum, maximum) (1, 14) (1, 12) (1, 14)
Distribution of inpatient stays (n, %)
1 42 (36.52) 48 (47.52) 90 (41.67)
2 41 (35.65) 31 (30.69) 72 (33.33)
Z2 32 (27.83) 22 (21.78) 54 (25.00)
Time to ﬁrst hospitalization since
diagnosis of
metastatic disease, mo
Mean (SD) 5.6 (7.3) 5.3 (6.4) 5.4 (6.9)
Median 2.7 3.0 2.9
Range (minimum, maximum) (0, 35.3) (0, 36.8) (0, 36.8)
Length of stay (among those with at
least 1 stay), d
Mean (SD) 15.3 (20.0) 7.7 (6.3) 11.7 (15.7)
Median 10.0 6.0 8.0
Range (minimum, maximum) (1, 112) (1, 52) (1, 112)
Long-term-care facility transfer (n,%) 21 (10.50) 7 (3.50) 28 (7.00)
Time to transfer to long-term-care
facility since diagnosis of metastatic
disease, mo
Mean (SD) 10.9 (11.9) 17. 4 (22.0) 11.9 (13.2)
Median 8.2 5.1 7.9
Range (minimum, maximum) (0, 43.2) (4.1, 42.8) (0, 43.2)
Hospice transfer (n,%) 39 (19.50) 81 (40.50) 120 (30.00)
(continued)
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Table VI. (continued).
Health Care Use
France
(n ¼ 200)
United Kingdom
(n ¼ 200)
Total Cohort
(N ¼ 400)
Time to transfer to hospice setting
since diagnosis of metastatic
disease, mo
Mean (SD) 12.3 (9.1) 10.9 (8.4) 11.4 (9.0)
Median 10.3 9 9.3
Range (minimum, maximum) (0.3, 39.1) (1.1, 44.0) (0.3, 44.0)
*Inpatient stay is an overnight or day admission, excluding emergency department visits.
Clinical Therapeuticscomparing results between countries are reported;
nevertheless, several apparent variations in practice
by country were noted.
Although there are still relatively few therapeutic
options for patients with metastatic pancreatic cancer,
FOLFIRINOX and gemcitabine plus nab-paclitaxel
provide new and meaningful alternatives to gemcita-
bine alone for patients who have good PS and normal
bilirubin levels. According to the European Society for
Medical Oncology–European Society of Digestive
Oncology guidelines,20 in addition to FOLFIRINOX
now being an option for patients, gemcitabine remains
a valid alternative for ﬁrst-line treatment of metastatic
disease. Gemcitabine-based combinations with cyto-
toxic agents (ie, 5-FU, capecitabine, irinotecan, cispla-
tin, and oxaliplatin) also are available; however,
supporting Phase 3 data have not conﬁrmed a major
survival advantage. The guidelines note limited evi-
dence supporting gemcitabine in combination with
either biologic agents or erlotinib in ﬁrst-line settings.
Although the combination of gemcitabine with erloti-
nib has been approved by the US Food and Drug
Administration and the EMA, the lack of clinically
meaningful efﬁcacy in the majority of patients may
limit the role of this regimen to use in the subgroup
most likely to beneﬁt. The most recent guidelines were
published before the availability of Phase 3 data
supporting the gemcitabine plus nab-paclitaxel com-
bination.7 Therefore, this regimen, although EMA-
approved,12 was not listed as an alternative at the time
this article was written. For those whose disease
progresses and are in need of a second-line therapy,
the combination of oxaliplatin and 5-FU can be1312administered to patients who received gemcitabine in
the ﬁrst-line setting; for patients who received FOL-
FIRINOX in the ﬁrst-line setting, single-agent gemci-
tabine is recommended.20
To our knowledge, our study is the ﬁrst to report
an increase in FOLFIRINOX use in select European
countries since publication of the Conroy et al8
clinical trial results in 2011. Although we found
gemcitabine alone to be used most commonly in
both countries to treat patients in ﬁrst-line metastatic
disease, FOLFIRINOX was used approximately twice
as frequently in France as in the United Kingdom,
which is perhaps a reﬂection of the fact that the
original trial data for the regimen were generated in
France. In both countries, the majority of patients
receiving FOLFIRINOX had better ECOG PS scores
than those treated with gemcitabine alone, and they
also experienced greater treatment-related toxicities
and discontinuation due to intolerance or toxicity.
Furthermore, a greater proportion of patients used
hematopoietic growth factors in France, which is
perhaps due in part to greater FOLFIRINOX use
and the need to manage side effects of this treatment
or potentially due to reimbursement considerations.
These results suggest that the lower observed rates of
Grade 3 or 4 neutropenia and neutropenic fever
associated with FOLFIRINOX use in France than in
the United Kingdom may have been due to the
increased use of granulocyte colony stimulating fac-
tors in France.
We found that only a small proportion of patients
received more than one line of systemic therapy for
metastatic disease, which reinforces the aggressivenessVolume 37 Number 6
E.N. Smyth et al.of this disease and the lack of therapeutic options in
this space. Sufﬁcient palliation is especially relevant
for these patients given the unique nature of the
disease, including secondary complications; end of life
is often marked by severe symptoms and poor quality
of life.21 Multidisciplinary management of symptoms
due to biliary obstruction, gastric outlet obstruction,
and cancer-related pain are of primary importance.19
To our knowledge, no detailed studies of the
real-world frequency of complications of pancreatic
cancer in any European country have been published
to date. More than half of the patients in our study
experienced disease complications during the period
of metastatic disease, and a greater proportion would
be expected to experience these with longer follow-up
times. As expected with this disease, obstruction
(biliary or duodenal), cachexia, and malnutrition were
the most frequently observed complications in both
France and the United Kingdom. In addition, a
supplementary analysis of the study data presented
here suggested that there was an association between
the presence of complications and select measures of
health care resource use. In both countries, patients
who experienced complications were more likely to be
hospitalized than those who did not; in France,
patients with complications were more likely to have
an ofﬁce and emergency department visit than those
who did not have a complication. Further research is
warranted to further conﬁrm these associations, as
well as to quantify the speciﬁc costs associated with
treating complications in this population, because they
are likely to be signiﬁcant.
One of the objectives of our study was to estimate
the frequency of Grade 3 or 4 adverse events in a real-
world setting. The frequency of Grade 3 or 4 adverse
events in our study was less than would be expected
for patients participating in clinical trials, owing to the
retrospective nature of the data collection. However,
in a relative sense, and consistent with results pre-
sented by Conroy et al,8 our study demonstrated that
patients who received FOLFIRINOX experienced
Grade 3 or 4 adverse events with greater frequency
than patients receiving gemcitabine as ﬁrst-line ther-
apy for metastatic disease. Overall, the top-3 Grade 3
or 4 adverse events reported for patients receiving
FOLFIRINOX included neutropenic fever followed by
thrombocytopenia and paresthesia/sensory neuropa-
thy. For gemcitabine, the most common included
thrombocytopenia followed by fatigue/lethargy, thenJune 2015asthenia and anemia that occurred in equal numbers
of patients.
It is our belief that patients in our study are likely
to be generally representative of the population of
patients who receive cancer-directed therapy for meta-
static pancreatic adenocarcinoma in France and the
United Kingdom, given the geographic representative-
ness of the population, concurrent comorbidities, and
presence of disease complications. In addition, our
observed patterns of treatment are consistent with
what might be expected after the availability of data
characterizing the overall survival beneﬁt of FOLFIR-
INOX. Patients in this study were younger on average
than in the general population of patients with
metastatic pancreatic cancer, possibly owing to the
requirement that all patients had to have received
cancer-directed therapy for metastatic disease in addi-
tion to having a minimum of 3 months of medical
record data available for review. For example, 47% of
all incident cases of pancreatic cancer in the United
Kingdom between 2009 and 2011 were among pa-
tients older than 75 years,22 whereas in our study only
8.5% of patients with pancreatic cancer (any stage) in
the United Kingdom were older than age 75 years at
diagnosis. Population-based data on PS are not avail-
able for patients receiving chemotherapy for meta-
static pancreatic cancer in France and the United
Kingdom; however, the distribution of PS scores that
we observed were comparable to patients enrolled in
recently published clinical trials of metastatic pancre-
atic cancer treatment.23,24
To our knowledge, our study is the ﬁrst retrospec-
tive analysis in any European country to report
information on health care resource and patterns of
systemic therapy use across multiple lines of therapy
for patients with metastatic pancreatic cancer. Fur-
thermore, limited data have been published to date in
the United States on these objectives. Studies including
the time period after presentation (June 2010) and
publication (May 2011) of the Phase 3 FOLFIRINOX
results are even further limited. Our study includes
follow-up through December 2012, Cartwright et al10
through November 2013, and DaCosta Byﬁeld et al25
through December 2010.
Consistent with our ﬁndings, Cartwright et al,10
previously demonstrated an increase in FOLFIRINOX
use and decrease in gemcitabine use in patients with good
PS treated in a network of US private oncology practices.
Dacosta Byﬁeld et al25 reported gemcitabine as the most1313
Clinical Therapeuticscommon systemic therapy received among patients with
metastatic pancreatic cancer in a large, US-managed
health care organization; however, follow-up extended
just 6 months postpresentation of FOLFIRINOX Phase 3
results. Rates of ofﬁce visits were noted as a signiﬁcant
driver of resource use relative to the control population,
in addition to outpatient, inpatient, and emergency
department visits with inpatient costs identiﬁed as the
single largest cost driver. O’Neill et al26 evaluated direct
medical costs of patients older than age 65 years with
locoregional or distant pancreatic cancer in the US
Surveillance, Epidemiology, and End Results–Medicare
database and found inpatient hospitalizations accounting
for the largest proportion of costs for patients with distant
disease. No details on systemic therapy treatment patterns
were reported.26 Lastly, Neiderhuber et al27 published
ﬁndings from the US National Cancer Data Base
outlining practice patterns in patients with pancreatic
cancer from 1985–1986 to 1991. The authors found that
66.1% of patients with Stage IV disease did not receive
any systemic treatment. No details on chemotherapy
regimens were reported for the 33.9% who were treated.
Our study is subject to several limitations inherent
to many retrospective medical record review studies.
In particular, patients selected for study inclusion
represented a convenience sample, in that the records
were obtained from physicians who were willing to
participate in the study. In addition, we imposed soft
quotas for geographic distribution, not only to gain a
better sense of the range of practice throughout each
country, but also to avoid the results being affected
too strongly by practice in densely populated urban
areas. As a consequence of these design decisions, as
well as an unknown extent to which physicians might
self-select for participating in a study such as this, our
ﬁndings may be limited when generalizing to the
overall pancreatic cancer population in the countries
we studied. Furthermore, owing to the observational
nature of this study and the limited control of
potential confounding, the results presented here are
descriptive and do not purport to show causal
relationships. Caution should be exercised in compar-
ing results between the 2 countries studied, which
differ with regard to the organization of medical care,
country-speciﬁc considerations regarding patient ac-
cess to care and medicines, and other cultural factors.
The data we analyzed were entered directly by the
treating physicians based on medical records available
at the time of data entry, and therefore are potentially1314subject to data entry errors and other limitations of
retrospective data capture. Although we used auto-
mated data checks to maximize internal data consis-
tency, responses were not validated against the
patients’ medical records by an independent reviewer.
Physicians were, however, asked to provide additional
clarifying details if any conﬂicting responses were
found within the data collection form. In addition,
to increase the likelihood that physicians responded
fully and accurately, the data collection form was
designed to limit physicians’ time burden. Therefore,
the information collected was not exhaustive, and
there could be additional measures that would be
useful in understanding variations in treatment and
outcomes that were not captured. Furthermore, physi-
cians reported data based on information available in
the patients’ medical records to which they had access.
Although major events such as inpatient hospital-
izations are likely to have been recorded, it is possible
that patients could have received health care services
in other care settings that were not reported back to
the treating physician and, therefore, were not part of
their medical record and not captured in this study. In
France, many patients are seen for consultation in
hospital outpatient settings as opposed to a physi-
cian’s ofﬁce. We did not collect information speciﬁc to
hospital outpatient settings, which also may help to
explain the lower observed rate of ofﬁce visits for
France compared with the United Kingdom. Finally,
19% of patients in our study were still receiving
FOLFIRINOX at the time of data collection. There-
fore, the opportunity to observe any safety or toler-
ability considerations for those patients and/or failure
of therapy due to disease progression was reduced and
should be taken into account when reviewing the
results of this study.
CONCLUSIONS
Despite these limitations, our study captures detailed
and generally representative clinical and treatment
data for patients with metastatic pancreatic cancer in
real-world settings in 2 large European countries.
Future research efforts are warranted to evaluate
patterns of cancer-directed and supportive care treat-
ment, frequency of complications, and health care
resource use in countries other than France and the
United Kingdom. Continuing assessments of future
changes in treatment patterns as a result of recent
regulatory decisions in support of gemcitabine plusVolume 37 Number 6
E.N. Smyth et al.nab-paclitaxel, as well as modiﬁed FOLFIRINOX
regimens that might be used in an effort to minimize
toxicity, will add important information to the body
of knowledge in the area of pancreatic cancer treat-
ment. Furthermore, a more comprehensive assessment
of the distribution of costs for this patient population
would be informative.ACKNOWLEDGMENTS
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